Dr. Brad McGregor

Like I have patients that get it and they're like very worried about what that CTA is going to be.

And I think as we think about how this works in the clinic, I think there's, I mean, I think the positive testing, super informative.

I'm still not quite sure to do in that negative setting.

So it depends on the situation.

So if I have a patient who has had a cystectomy and has T2, a worse disease, and is sending me out to chemotherapy, I'm getting NGS on that patient because I want to know if there's something that I can do.

I'm going to get HER2 tests on that patient because now we have data for TDXD for a patient who are HER2 positive.

Because that information is going to help me choose the therapy for the patient if I need it.

And I think that's far more helpful in that situation than the CTA, which is great, but it can be more predictive, prognostic.

I mean, I think that some of the information we get from the tumors can truly help us choose which of the therapies make the most sense.

If you look at the perioperative management,

it's sort of like the same for all, right?

I think it's going to be EV PEMBRO for all likely is going to be the answer in 12 to maybe 6 to 18 months as you get this data.

But we know that patients may relapse and everything.

And so then to that point, what do we do after EV PEMBRO either in the pair-up study or the metastatic setting?

And that's where getting like FGFR or HER2 IHC can be super helpful.

Especially as HER2 ADCs are maybe going to move.

We have data of them maybe trying to move into the frontline setting.

We had some nice data from China with DV and HER2 down to 1+.

So I don't know.

I think the role of HER2 ADCs with the new ADCs, the better linkers, better delivery payloads is evolving rapidly in body cancer as well.